Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Ectopic expression of Flt3 kinase inhibits proliferation and promotes cell death in different human cancer cell lines.

Oveland E, Wergeland L, Hovland R, Lorens JB, Gjertsen BT, Fladmark KE.

Cell Biol Toxicol. 2012 Aug;28(4):201-12. doi: 10.1007/s10565-012-9216-z.

PMID:
22422053
2.

Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax.

Lisovsky M, Estrov Z, Zhang X, Consoli U, Sanchez-Williams G, Snell V, Munker R, Goodacre A, Savchenko V, Andreeff M.

Blood. 1996 Nov 15;88(10):3987-97.

3.

The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.

Spiekermann K, Dirschinger RJ, Schwab R, Bagrintseva K, Faber F, Buske C, Schnittger S, Kelly LM, Gilliland DG, Hiddemann W.

Blood. 2003 Feb 15;101(4):1494-504.

4.

Effect of small interfering RNA targeting wild-type FLT3 in acute myeloid leukaemia cells in vitro and in vivo.

Wang CM, Sheng GY, Lu J, Xie L, Bai ST, Xu XJ, Liu YF.

J Int Med Res. 2011;39(5):1661-74.

PMID:
22117966
5.

ATRA can enhance apoptosis that is induced by Flt3 tyrosine kinase inhibition in Flt3-ITD positive cells.

Scholl S, Müller R, Clement JH, Loncarevic IF, Böhmer FD, Höffken K.

Leuk Res. 2006 May;30(5):633-42.

PMID:
16473406
6.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M.

J Natl Cancer Inst. 2008 Feb 6;100(3):184-98. doi: 10.1093/jnci/djm328.

7.

Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signaling.

Arora D, Stopp S, Böhmer SA, Schons J, Godfrey R, Masson K, Razumovskaya E, Rönnstrand L, Tänzer S, Bauer R, Böhmer FD, Müller JP.

J Biol Chem. 2011 Apr 1;286(13):10918-29. doi: 10.1074/jbc.M110.205021.

8.

Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3.

Fukuda S, Singh P, Moh A, Abe M, Conway EM, Boswell HS, Yamaguchi S, Fu XY, Pelus LM.

Blood. 2009 Jul 9;114(2):394-403. doi: 10.1182/blood-2008-11-188714.

9.

AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.

Barbarroja N, Torres LA, Rodriguez-Ariza A, Valverde-Estepa A, Lopez-Sanchez LM, Ruiz-Limon P, Perez-Sanchez C, Carretero RM, Velasco F, López-Pedrera C.

Exp Hematol. 2010 Aug;38(8):641-52. doi: 10.1016/j.exphem.2010.03.017.

PMID:
20380868
10.

Effects of FLT3 ligand on proliferation and survival of myeloid leukemia cells.

Drexler HG, Meyer C, Quentmeier H.

Leuk Lymphoma. 1999 Mar;33(1-2):83-91. Review.

PMID:
10194124
11.

Constitutively activated FLT3 phosphorylates BAD partially through pim-1.

Kim KT, Levis M, Small D.

Br J Haematol. 2006 Sep;134(5):500-9.

PMID:
16869825
12.

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.

Yee KW, O'Farrell AM, Smolich BD, Cherrington JM, McMahon G, Wait CL, McGreevey LS, Griffith DJ, Heinrich MC.

Blood. 2002 Oct 15;100(8):2941-9.

13.

The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.

Grundy M, Seedhouse C, Shang S, Richardson J, Russell N, Pallis M.

Mol Cancer Ther. 2010 Mar;9(3):661-72. doi: 10.1158/1535-7163.MCT-09-1144.

14.

[Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].

Müller-Tidow C, Steur C, Mizuki M, Schwäble J, Brandts C, Berdel WE, Serve H.

Dtsch Med Wochenschr. 2002 Oct 18;127(42):2195-200. German.

PMID:
12397548
15.

CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.

Lopes de Menezes DE, Peng J, Garrett EN, Louie SG, Lee SH, Wiesmann M, Tang Y, Shephard L, Goldbeck C, Oei Y, Ye H, Aukerman SL, Heise C.

Clin Cancer Res. 2005 Jul 15;11(14):5281-91.

16.
17.

Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.

Adam M, Pogacic V, Bendit M, Chappuis R, Nawijn MC, Duyster J, Fox CJ, Thompson CB, Cools J, Schwaller J.

Cancer Res. 2006 Apr 1;66(7):3828-35.

18.

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

Kelly LM, Yu JC, Boulton CL, Apatira M, Li J, Sullivan CM, Williams I, Amaral SM, Curley DP, Duclos N, Neuberg D, Scarborough RM, Pandey A, Hollenbach S, Abe K, Lokker NA, Gilliland DG, Giese NA.

Cancer Cell. 2002 Jun;1(5):421-32.

PMID:
12124172
19.

The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia.

Del Poeta G, Ammatuna E, Lavorgna S, Capelli G, Zaza S, Luciano F, Ottone T, Del Principe MI, Buccisano F, Maurillo L, Panetta P, de Fabritiis P, Stasi R, Venditti A, Amadori S, Lo Coco F.

Br J Haematol. 2010 May;149(3):383-7. doi: 10.1111/j.1365-2141.2010.08098.x.

PMID:
20148885
20.

Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53.

Irish JM, Anensen N, Hovland R, Skavland J, Børresen-Dale AL, Bruserud O, Nolan GP, Gjertsen BT.

Blood. 2007 Mar 15;109(6):2589-96.

Items per page

Supplemental Content

Support Center